Factors Determining the Rate of Adoption of Pharmaceutical Recommendations by Patients in Primary Care Following a Medication Review by a Pharmacist (REVMedAdopt)
Polypharmacy is a growing public health concern associated with adverse drug events, drug interactions, and hospitalizations. Medication reviews (MedRev) are structured evaluations of patients' medications aiming to optimize treatment and improve outcomes. In Belgium, a reimbursed MedRev service involving community pharmacists and general practitioners (GPs) has been implemented since 2023.
The RevMedAdopt Pharmacy Study is a national prospective interventional study evaluating the real-world implementation of pharmaceutical recommendations generated during medication reviews performed by supervised final-year pharmacy students.
The primary objective is to assess the adoption rate of pharmaceutical recommendations at 3 and 6 months after the medication review. Recommendations are categorized as fully adopted, partially adopted, not adopted, or unavailable.
Secondary objectives are to identify factors associated with recommendation implementation, including patient characteristics, pharmacist and GP collaboration, medication review processes, and recommendation-related factors.
The study includes adult polymedicated patients living at home in Belgium and followed by both a GP and a reference pharmacist. Approximately 120 patients will be recruited.
Medication reviews are conducted during pharmacy internships following the official Belgian MedRev framework. Recommendations validated by supervising pharmacists are communicated to GPs. Follow-up data are collected through telephone interviews with patients and GPs. Qualitative interviews with patients, pharmacists, and GPs explore barriers and facilitators influencing recommendation adoption.
This mixed-methods study aims to improve understanding of the implementation of pharmacist-led medication review recommendations in primary care and to support optimization of interprofessional collaboration and medication review services.
研究概览
详细说明
Polypharmacy represents a major public health issue, particularly among patients with chronic conditions, and is associated with increased risks of adverse drug events, drug-drug interactions, inappropriate prescribing, and hospitalizations. Medication reviews (MedRev), defined as structured and systematic evaluations of a patient's medication regimen, aim to optimize medication use, improve adherence, and enhance clinical outcomes.
In Belgium, a reimbursed medication review service has been implemented in community pharmacies since April 2023, promoting collaboration between community pharmacists (CPs) and general practitioners (GPs). However, while such interventions generate pharmaceutical recommendations, their real-world implementation remains variable and insufficiently understood. Previous studies suggest that contextual factors, particularly related to interprofessional collaboration and communication, play a key role in determining whether recommendations are effectively adopted.
The RevMedAdopt Pharmacy Study is a national prospective interventional study designed to evaluate the implementation of this MedRev service in real-life conditions. The study is embedded within the clinical training of final-year pharmacy students, who perform medication reviews under the supervision of accredited community pharmacists.
The primary objective is to assess the adoption rate of pharmaceutical recommendations issued following medication reviews. Adoption is defined as the extent to which recommendations are implemented in the patient's medication regimen and is categorized as fully adopted, partially adopted (alternative action taken), not adopted, or unavailable. This outcome is measured at two time points: 3 months after the intervention (via patient follow-up) and 6 months after the intervention (via GP follow-up).
Secondary objectives are to identify and assess contextual factors associated with the successful implementation of recommendations. These factors include patient-related characteristics (e.g., socio-demographic profile, comorbidities, medication burden), pharmacist-related aspects (e.g., supervision, role as reference pharmacist), GP-related aspects (e.g., involvement, collaboration with pharmacists), characteristics of the medication review process (e.g., access to clinical data, communication channels), and characteristics of the recommendations themselves (e.g., type and clinical relevance).
The study population consists of adult patients living at home in Belgium who are polymedicated (defined as the use of five or more chronic reimbursed medications), and who have both a general practitioner and a reference pharmacist. Patients with insufficient language proficiency or without adequate support in case of cognitive impairment are excluded. Approximately 120 participants will be recruited in the first phase, an initial phase involving UCLouvain students. It is possible that we do an extension to other Belgian universities.
The study is conducted in several sequential steps. First, pharmacy students recruit eligible patients, obtain informed consent, and conduct medication reviews, including patient interviews and pharmacotherapeutic analyses. Drug-related problems are identified, and recommendations are formulated and validated by supervising pharmacists. These recommendations are then communicated to the GP, primarily via an official electronic form (eForm), possibly complemented by additional communication methods.
Follow-up is conducted by the research team. At 3 months, patients are contacted by telephone to update their medication list and assess changes. At 6 months, GPs are contacted to confirm medication changes, evaluate recommendation implementation, and collect additional clinical information. These data allow for a pre-post comparison of medication regimens and calculation of adoption rates.
In addition to quantitative data collection, a qualitative component is conducted through semi-structured interviews with a subset of patients, GPs, and pharmacists. These interviews explore experiences, perceptions, barriers, and facilitators related to medication reviews and the implementation of recommendations.
Data are collected using REDCap, ensuring secure and standardized data management in compliance with GDPR regulations. Quantitative analyses will assess adoption rates and their associations with contextual factors, while qualitative analyses will follow a thematic approach to identify key determinants of implementation.
By combining quantitative and qualitative methods, this study aims to provide a comprehensive understanding of the mechanisms underlying the adoption of pharmacist-led medication review recommendations. The findings are expected to inform improvements in the organization, communication, and effectiveness of medication review services, and to support the development of integrated, patient-centered care models in primary care settings.
研究类型
注册 (实际的)
阶段
- 不适用
联系人和位置
学习地点
-
-
-
Woluwe-Saint-Lambert、比利时、1200
- Campus Woluwé
-
-
参与标准
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
描述
Inclusion Criteria:
- Adult patients (≥18 years old) living at home
- French-speaking patients, or patients with a close caregiver able to communicate in French
- Patients with polypharmacy (defined as the use of five or more reimbursed chronic medications)
- Patients undergoing an official structured medication review performed by final-year UCLouvain pharmacy students
- Patients able to provide informed consent
- Patients with an identified referent general practitioner and referent pharmacist
Exclusion Criteria:
- Patients not meeting the inclusion criteria
学习计划
研究是如何设计的?
设计细节
- 主要用途:卫生服务研究
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:RevMedAdopt intervention
Participants receive a structured medication review conducted by last-year pharmacy students, including identification of drug-related problems and communication of recommendations to the treating general practitioner and/or patient.
|
The intervention consists of a structured medication review performed by trained healthcare students. This process includes the systematic identification of drug-related problems (DRPs), such as inappropriate medications, drug-drug interactions, dosing issues, therapeutic duplications, and adherence-related concerns. Based on this assessment, individualized recommendations are formulated to optimize pharmacotherapy. These interventions may include medication discontinuation (deprescribing), dose adjustment, initiation of appropriate therapies, or patient education. Recommendations are communicated to the GP and/or directly to the patient, depending on the nature of the intervention. The implementation and adoption of these recommendations are subsequently evaluated during follow-ups at 3 and 6 months |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Adoption rate of medication review recommendations
大体时间:3 and 6 months
|
Proportion of medication review recommendations (related to drug-related problems, DRPs) that are implemented by the GP and/or the patient following communication.
|
3 and 6 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Number and types of drug-related problems identified
大体时间:baseline
|
Number of drug-related problems (DRPs) identified during the medication review, categorized by type.
|
baseline
|
|
Number and types of recommendations formulated
大体时间:Baseline
|
Number of recommendations formulated to address identified DRPs, categorized by type of intervention, such as deprescribing, dose adjustment, treatment initiation, monitoring, or patient education.
|
Baseline
|
|
Patient characteristics
大体时间:Baseline
|
Description of baseline patient characteristics, including demographic, clinical, and medication-related variables.
|
Baseline
|
|
Intensity and mode of communication between pharmacist and GP
大体时间:From baseline to 6 months
|
Assessment of the intensity and mode of communication between the pharmacist and the GP, including the number and type of contacts used to discuss medication review recommendations.
|
From baseline to 6 months
|
|
Communication pathway of recommendations
大体时间:From baseline to 6 months
|
Description of how medication review recommendations are communicated, including communication via the GP, directly to the patient, or other mean.
|
From baseline to 6 months
|
其他结果措施
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Adoption rate according to recommendation type
大体时间:6 months
|
Proportion of recommendations implemented according to their type.
|
6 months
|
|
Adoption rate according to communication pathway
大体时间:6 months
|
Proportion of recommendations implemented depending on the communication method (GP-directed, patient-mediated, or other).
|
6 months
|
合作者和调查者
调查人员
- 研究主任:Olivia Dalleur, PhD, Professor、Université Catholique de Louvain
- 首席研究员:Manon de Montigny、Université Catholique de Louvain
出版物和有用的链接
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
关键字
其他研究编号
- REVMEDADOPT 2025/03/NOV/450
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.